Latest Immunocellular Thera (IMUC) Headlines
Post# of 18
Posted On: 03/10/2014 6:25:08 AM
Latest Immunocellular Thera (IMUC) Headlines
3 Stocks Under $10 Moving Higher
at The Street - Fri Mar 07, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
ImmunoCellular Therapeutics to Report Financial Results for the Fourth Quarter and Full Year 2013 on March 13, 2014
PR Newswire - Tue Mar 04, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report fourth quarter and full year 2013 financial results on Thursday, March 13, 2014. ImmunoCellular will host a conference call and webcast to discuss its financial results and provide a business update at 5:00 pm ET that day. The call will be hosted by Andrew Gengos, President and CEO.
Northwest Bio: Interim Analysis of Brain Cancer Vaccine Study Past Due
at The Street - Mon Mar 03, 9:32AM CST
Twelve weeks have passed since Northwest Bio said an interim analysis of the DCVax phase III study was underway. Where are the results?
ImmunoCellular Therapeutics to Present at ROTH Conference on March 11th
PR Newswire - Mon Mar 03, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the 26th Annual ROTH Conference on Tuesday, March 11, 2014 at 5:00 pm PT, at the Ritz-Carlton Hotel, Laguna Niguel, CA.
Strength Seen in ImmunoCellular Therapeutics, Ltd. (IMUC): Stock Soars 14.05% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 7:44AM CST
ImmunoCellular Therapeutics, Ltd. was a big mover last session, as the company saw its shares surge 14% on the day.
ImmunoCellular Therapeutics Receives Orphan Drug Status for ICT-107 in Glioblastoma in the European Union
PR Newswire - Tue Feb 25, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced that the European Medicines Agency (EMA) has granted orphan drug designation for ICT-107 for the treatment of patients with glioblastoma. Granting of orphan drug status in the EU provides sponsor companies with incentives, including a 10-year period of market exclusivity, access to a centralized review process, trial design assistance and scientific advice during product development, fee reductions, and tax incentives. ImmunoCellular has previously received orphan designation for ICT-107 in glioblastoma in the US.
ImmunoCellular Therapeutics' Founder and Chief Scientific Officer, John Yu, MD, Presents at "Targeting Cancer Stem Cells" Symposium
PR Newswire - Fri Feb 14, 3:00PM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that the Company's Founder and Chief Scientific Officer, John S. Yu, MD, delivered a presentation highlighting the therapeutic importance of utilizing antigen-specific dendritic cell (DC) cancer vaccines for inducing a potent T-cell response and destroying tumor cells as well as cancer stem cells. Dr. Yu's presentation took place today in a session titled "Dendritic Cell Vaccines Targeting Cancer Stem Cells" at Cambridge Healthtech Institute's Third Annual "Targeting Cancer Stem Cells: New Opportunities for Oncology Therapeutics," which is part of the 21st Annual Molecular Medicine Tri Conference, in San Francisco.
5 Stocks Under $10 Set to Soar
at The Street - Thu Feb 13, 12:58PM CST
These under-$10 stocks look ready to trade higher from current levels.
Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013
M2 - Thu Feb 13, 2:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/dcl2zl/recurrent) has announced the addition of the "Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013" report to their offering. 'Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Recurrent Glioblastoma Multiforme (GBM), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Recurrent Glioblastoma Multiforme (GBM). Key Topics Covered: Introduction Recurrent Glioblastoma Multiforme (GBM) Overview Therapeutics Development Clinical Stage Products Early Stage Products Drug Profiles bosutinib - Drug Profile axitinib - Drug Profile onartuzumab - Drug Profile dacomitinib - Drug Profile rindopepimut - Drug Profile VB-111 - Drug Profile ANG-1005 - Drug Profile AT-101 - Drug Profile vorinostat - Drug Profile buparlisib hydrochloride - Drug Profile pazopanib hydrochloride - Drug Profile memantine hydrochloride - Drug Profile galunisertib - Drug Profile G-200 - Drug Profile ERC-1671 - Drug Profile lenvatinib - Drug Profile trebananib - Drug Profile TB-403 - Drug Profile nabiximols - Drug Profile golvatinib - Drug Profile ARC-100 - Drug Profile New Castle Disease Virus - HUJ Oncolytic Virus - Drug Profile vocimagene amiretrorepvec flucytosine ER - Drug Profile golvatinib lenvatinib - Drug Profile ICT-121 - Drug Profile BTSC mRNA Loaded Dendritic Cell Vaccine - Drug Profile AZD-7451 - Drug Profile DNX-2401 - Drug Profile OS-2966 - Drug Profile Recurrent Glioblastoma Multiforme (GBM) - Recent Pipeline Updates Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects Recurrent Glioblastoma Multiforme (GBM) - Product Development Milestones Featured News & Press Releases Appendix Companies Mentioned F. Hoffmann-La Roche Ltd. Amgen Inc. AstraZeneca PLC Eli Lilly and Company GlaxoSmithKline plc Agenus, Inc. Merck & Co., Inc. Novartis AG Eisai Co., Ltd. Pfizer Inc. GW Pharmaceuticals plc Celldex Therapeutics, Inc. ImmunoCellular Therapeutics, Ltd. ThromboGenics NV AngioChem Inc. Ascenta Therapeutics, Inc. Vascular Biogenics Ltd. Archer Biosciences, Inc Tocagen Inc. DNAtrix, Inc. ERC Belgium SA OncoSynergy Inc For more information visit http://www.researchandmarkets.com/research/dcl2zl/recurrent About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
3 Possible Catalysts for Inovio Pharmaceuticals in 2014
Peter Stephens, The Motley Fool - Motley Fool - Wed Feb 12, 4:01PM CST
There's a real buzz around Inovio Pharmaceuticals . Indeed, shares have have risen from $0.72 one year ago to $2.82 at the time of writing . That's a gain of 291%. I don't need to tell you that the major U.S. indices posted gains that were only...
ImmunoCellular Therapeutics to Present at the BIO CEO & Investor Conference on February 10, 2014
PR Newswire - Mon Feb 03, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer, will present a corporate overview and business update at the 16th Annual BIO CEO & Investor Conference at 1:30 pm ET on Monday, February 10, 2014, at the Waldorf Astoria Hotel in New York City.
ImmunoCellular Therapeutics' ICT-107 - Is 2013 the year of glioblastoma vaccines
PR Newswire Europe - Wed Jan 29, 4:02PM CST
DUBLIN, Ireland, January 29, 2014 /PRNewswire/ --
Strength Seen in ImmunoCellular Therapeutics (IMUC): Stock Surges 18.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 21, 7:44AM CST
ImmunoCellular Therapeutics, Ltd. was a big mover last session, as the company saw its shares rally over 18% on the day.
ImmunoCellular Therapeutics Provides Update on 2014 Corporate Strategies and Milestones
PR Newswire - Mon Jan 13, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today provided an update on the Company's anticipated 2014 corporate strategies and milestones.
ImmunoCellular Therapeutics Issues Shareholder Letter Providing Update on ICT-107 Program in Newly Diagnosed Glioblastoma
PR Newswire - Thu Jan 09, 3:38PM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today issued the following letter to shareholders providing an update on the Company's ICT-107 clinical program in patients with newly diagnosed glioblastoma (GBM).
Biotech Stock Mailbag: Inovio, Chelsea, Exelixis, Ariad, ImmunoCellular
at The Street - Fri Jan 03, 7:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Special Stocks Analysis: ImmunoCellular Therapeutics, Vodafone Group, BlackBerry Ltd, Galena Biopharma Inc
ACCESSWIRE - Tue Dec 24, 9:04AM CST
New York, December 24, 2013 / Accesswire / - Market Buzz Report, which provides live alerts on penny stocks, issues critical stocks analysis for Vodafone Group Plc (ADR) (NASDAQ:VOD), BlackBerry Ltd (NASDAQ:BBRY), Galena Biopharma Inc (NASDAQ:GALE), ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC).
ImmunoCellular Therapeutics Announces First Patient Receives Vaccine in Phase I Trial of Cancer Vaccine ICT-121 in Recurrent Glioblastoma
Business Wire - Mon Dec 23, 3:00PM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced today that the first patient in the phase I clinical trial of ICT-121, a cancer vaccine targeting recurrent glioblastoma multiforme (GBM, or brain cancer), has received the vaccine. ICT-121 is a dendritic cell vaccine targeting CD-133, an important cancer stem cell marker that is commonly expressed on a broad range of solid tumors. The investigator-sponsored phase I trial is being conducted at Cedars-Sinai Medical Center in Los Angeles, CA. ImmunoCellular is supporting the trial by providing the ICT-121 vaccine.
Form 4: Update Filing for ImmunoCellular Therapeutics Lt (IMUC)
Vickers Stock Research - Thu Dec 19, 5:38AM CST
Incap Corporation
3 Stocks Under $10 Moving Higher
at The Street - Fri Mar 07, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
ImmunoCellular Therapeutics to Report Financial Results for the Fourth Quarter and Full Year 2013 on March 13, 2014
PR Newswire - Tue Mar 04, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report fourth quarter and full year 2013 financial results on Thursday, March 13, 2014. ImmunoCellular will host a conference call and webcast to discuss its financial results and provide a business update at 5:00 pm ET that day. The call will be hosted by Andrew Gengos, President and CEO.
Northwest Bio: Interim Analysis of Brain Cancer Vaccine Study Past Due
at The Street - Mon Mar 03, 9:32AM CST
Twelve weeks have passed since Northwest Bio said an interim analysis of the DCVax phase III study was underway. Where are the results?
ImmunoCellular Therapeutics to Present at ROTH Conference on March 11th
PR Newswire - Mon Mar 03, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the 26th Annual ROTH Conference on Tuesday, March 11, 2014 at 5:00 pm PT, at the Ritz-Carlton Hotel, Laguna Niguel, CA.
Strength Seen in ImmunoCellular Therapeutics, Ltd. (IMUC): Stock Soars 14.05% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 7:44AM CST
ImmunoCellular Therapeutics, Ltd. was a big mover last session, as the company saw its shares surge 14% on the day.
ImmunoCellular Therapeutics Receives Orphan Drug Status for ICT-107 in Glioblastoma in the European Union
PR Newswire - Tue Feb 25, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced that the European Medicines Agency (EMA) has granted orphan drug designation for ICT-107 for the treatment of patients with glioblastoma. Granting of orphan drug status in the EU provides sponsor companies with incentives, including a 10-year period of market exclusivity, access to a centralized review process, trial design assistance and scientific advice during product development, fee reductions, and tax incentives. ImmunoCellular has previously received orphan designation for ICT-107 in glioblastoma in the US.
ImmunoCellular Therapeutics' Founder and Chief Scientific Officer, John Yu, MD, Presents at "Targeting Cancer Stem Cells" Symposium
PR Newswire - Fri Feb 14, 3:00PM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that the Company's Founder and Chief Scientific Officer, John S. Yu, MD, delivered a presentation highlighting the therapeutic importance of utilizing antigen-specific dendritic cell (DC) cancer vaccines for inducing a potent T-cell response and destroying tumor cells as well as cancer stem cells. Dr. Yu's presentation took place today in a session titled "Dendritic Cell Vaccines Targeting Cancer Stem Cells" at Cambridge Healthtech Institute's Third Annual "Targeting Cancer Stem Cells: New Opportunities for Oncology Therapeutics," which is part of the 21st Annual Molecular Medicine Tri Conference, in San Francisco.
5 Stocks Under $10 Set to Soar
at The Street - Thu Feb 13, 12:58PM CST
These under-$10 stocks look ready to trade higher from current levels.
Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013
M2 - Thu Feb 13, 2:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/dcl2zl/recurrent) has announced the addition of the "Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013" report to their offering. 'Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Recurrent Glioblastoma Multiforme (GBM), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Recurrent Glioblastoma Multiforme (GBM). Key Topics Covered: Introduction Recurrent Glioblastoma Multiforme (GBM) Overview Therapeutics Development Clinical Stage Products Early Stage Products Drug Profiles bosutinib - Drug Profile axitinib - Drug Profile onartuzumab - Drug Profile dacomitinib - Drug Profile rindopepimut - Drug Profile VB-111 - Drug Profile ANG-1005 - Drug Profile AT-101 - Drug Profile vorinostat - Drug Profile buparlisib hydrochloride - Drug Profile pazopanib hydrochloride - Drug Profile memantine hydrochloride - Drug Profile galunisertib - Drug Profile G-200 - Drug Profile ERC-1671 - Drug Profile lenvatinib - Drug Profile trebananib - Drug Profile TB-403 - Drug Profile nabiximols - Drug Profile golvatinib - Drug Profile ARC-100 - Drug Profile New Castle Disease Virus - HUJ Oncolytic Virus - Drug Profile vocimagene amiretrorepvec flucytosine ER - Drug Profile golvatinib lenvatinib - Drug Profile ICT-121 - Drug Profile BTSC mRNA Loaded Dendritic Cell Vaccine - Drug Profile AZD-7451 - Drug Profile DNX-2401 - Drug Profile OS-2966 - Drug Profile Recurrent Glioblastoma Multiforme (GBM) - Recent Pipeline Updates Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects Recurrent Glioblastoma Multiforme (GBM) - Product Development Milestones Featured News & Press Releases Appendix Companies Mentioned F. Hoffmann-La Roche Ltd. Amgen Inc. AstraZeneca PLC Eli Lilly and Company GlaxoSmithKline plc Agenus, Inc. Merck & Co., Inc. Novartis AG Eisai Co., Ltd. Pfizer Inc. GW Pharmaceuticals plc Celldex Therapeutics, Inc. ImmunoCellular Therapeutics, Ltd. ThromboGenics NV AngioChem Inc. Ascenta Therapeutics, Inc. Vascular Biogenics Ltd. Archer Biosciences, Inc Tocagen Inc. DNAtrix, Inc. ERC Belgium SA OncoSynergy Inc For more information visit http://www.researchandmarkets.com/research/dcl2zl/recurrent About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
3 Possible Catalysts for Inovio Pharmaceuticals in 2014
Peter Stephens, The Motley Fool - Motley Fool - Wed Feb 12, 4:01PM CST
There's a real buzz around Inovio Pharmaceuticals . Indeed, shares have have risen from $0.72 one year ago to $2.82 at the time of writing . That's a gain of 291%. I don't need to tell you that the major U.S. indices posted gains that were only...
ImmunoCellular Therapeutics to Present at the BIO CEO & Investor Conference on February 10, 2014
PR Newswire - Mon Feb 03, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer, will present a corporate overview and business update at the 16th Annual BIO CEO & Investor Conference at 1:30 pm ET on Monday, February 10, 2014, at the Waldorf Astoria Hotel in New York City.
ImmunoCellular Therapeutics' ICT-107 - Is 2013 the year of glioblastoma vaccines
PR Newswire Europe - Wed Jan 29, 4:02PM CST
DUBLIN, Ireland, January 29, 2014 /PRNewswire/ --
Strength Seen in ImmunoCellular Therapeutics (IMUC): Stock Surges 18.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 21, 7:44AM CST
ImmunoCellular Therapeutics, Ltd. was a big mover last session, as the company saw its shares rally over 18% on the day.
ImmunoCellular Therapeutics Provides Update on 2014 Corporate Strategies and Milestones
PR Newswire - Mon Jan 13, 5:00AM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today provided an update on the Company's anticipated 2014 corporate strategies and milestones.
ImmunoCellular Therapeutics Issues Shareholder Letter Providing Update on ICT-107 Program in Newly Diagnosed Glioblastoma
PR Newswire - Thu Jan 09, 3:38PM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today issued the following letter to shareholders providing an update on the Company's ICT-107 clinical program in patients with newly diagnosed glioblastoma (GBM).
Biotech Stock Mailbag: Inovio, Chelsea, Exelixis, Ariad, ImmunoCellular
at The Street - Fri Jan 03, 7:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Special Stocks Analysis: ImmunoCellular Therapeutics, Vodafone Group, BlackBerry Ltd, Galena Biopharma Inc
ACCESSWIRE - Tue Dec 24, 9:04AM CST
New York, December 24, 2013 / Accesswire / - Market Buzz Report, which provides live alerts on penny stocks, issues critical stocks analysis for Vodafone Group Plc (ADR) (NASDAQ:VOD), BlackBerry Ltd (NASDAQ:BBRY), Galena Biopharma Inc (NASDAQ:GALE), ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC).
ImmunoCellular Therapeutics Announces First Patient Receives Vaccine in Phase I Trial of Cancer Vaccine ICT-121 in Recurrent Glioblastoma
Business Wire - Mon Dec 23, 3:00PM CST
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced today that the first patient in the phase I clinical trial of ICT-121, a cancer vaccine targeting recurrent glioblastoma multiforme (GBM, or brain cancer), has received the vaccine. ICT-121 is a dendritic cell vaccine targeting CD-133, an important cancer stem cell marker that is commonly expressed on a broad range of solid tumors. The investigator-sponsored phase I trial is being conducted at Cedars-Sinai Medical Center in Los Angeles, CA. ImmunoCellular is supporting the trial by providing the ICT-121 vaccine.
Form 4: Update Filing for ImmunoCellular Therapeutics Lt (IMUC)
Vickers Stock Research - Thu Dec 19, 5:38AM CST
Incap Corporation
(0)
(0)